Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Intercure ( (IL:INCR) ) has shared an announcement.
InterCure Ltd. announced significant leadership changes and financial advancements. Ehud Barak is stepping down as Chairman, to be succeeded by CEO Alexander Rabinovich, who has led the company through substantial growth. InterCure has completed a financing round, securing approximately $18.2 million to support the recovery and expansion of its Nir Oz facility, with potential additional funds from warrants. The company is focused on executing a recovery plan post-war, aiming to restore operations and continue its expansion in international markets such as Germany, the UK, and Australia. This financing and leadership transition are strategic moves to ensure long-term stability and growth, positioning InterCure as a significant player in the pharmaceutical cannabis industry.
More about Intercure
InterCure Ltd., operating under the name Canndoc, is a leading and rapidly growing cannabis company outside North America. It is Israel’s largest licensed cannabis producer, known for offering GMP-certified and pharmaceutical-grade medical cannabis products. The company utilizes a vertically integrated ‘seed-to-sale’ model and has established strong international partnerships to cater to the global cannabis market.
YTD Price Performance: 5.63%
Average Trading Volume: 36,953
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $80.44M
For detailed information about INCR stock, go to TipRanks’ Stock Analysis page.
